ClinicalTrials.gg
TerminatedNCT01987960Updated Mar 13, 2017Results posted

Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)

A Phase 3 interventional study of Placebo and Brexpiprazole in Post-traumatic Stress Disorder and PTSD, sponsored by H. Lundbeck A/S. Terminated at 59 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-13.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated due to challenges with patient eligibility; the decision to terminate was not based on any safety concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
417
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 341 open to participants now, 404 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Enrollment
76th of 1,491
417 · median 65
Started
2013
with 69 others
Phase 3
64 of 1,664
8 open now
Registered
523rd of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 76th largest by enrollment of the 1,491 interventional ones that give a count, is one of 70 that started in 2013, is one of 64 in phase 3, and was the 523rd registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

341 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

336 more — sign in →

All 341 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy of brexpiprazole as adjunctive treatment to paroxetine (PAR) or sertraline (SER) on PTSD symptoms.

03

Conditions studied

  • Post-traumatic Stress Disorder
  • PTSD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has PTSD, diagnosed according to ™ and confirmed by the Mini International Neuropsychiatric Interview (MINI).
  • The patient has a Clinician-Administered PTSD Scale Part 2 (CAPS-2) total score ≥70 at Screening and Baseline Visits.
  • The reported duration of the PTSD is at least 3 months.

Exclusion criteria

Exclusion Criteria:

  • The index traumatic event that led to development of PTSD took place more than 15 years before screening.
  • The patient has a severe personality disorder that in the investigator's opinion may interfere with the conduct of the study.
  • The patient is at significant suicidal risk.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
417 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER)

    Drug: Placebo

  • Experimental
    Brexpiprazole

    Brexpiprazole adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER). Brexpiprazole dosing was 1mg/day for one week, followed by 2mg/day for 3 weeks. Thereafter the dose was flexible and could be adjusted from 1 to 3 mg/day.

    Drug: Brexpiprazole

Interventions

  • DrugPlacebo

    Once daily, tablets, orally

  • 1 to 3 mg/day, once daily dose, tablets, orally

06

What researchers measure

Primary outcomes

  1. PTSD Symptoms Using CAPS-2 Total Score

    Clinician-Administered PTSD Scale Part 2 (CAPS-2): 17 items in criteria B, C and D (Corresponding to CAPS-2) will be administered to provide a total score. They are rated on a 5 point scale for frequency from 0 (never or none) to 4 (daily or almost every day), and intensity from 0 (none) to 4 (extreme). The sum of the 17 items gives a toal score ranging from 0 to 136, with a higher score indicating greater symptom severity.

    Time frame: Period 2: Baseline to Week 12 (of randomized period)

Secondary outcomes

  1. Global Clinical Impression Severity of Illness (CGI-S) Score

    Clinical Global Impression - Severity of Illness (CGI-S) The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Period 2: Baseline to Week 12 (of randomized period)

07

Results

Posted Mar 13, 2017
Limitations and caveats
As the study was terminated limited efficacy and safety data were collected from the randomized patients. The data are descriptive and the primary and key secondary efficacy analyses were not done.

Participant flow

417 patients were enrolled to the study and 413 patients received open-label treatment with a commercially available treatment for PTSD (PAR/SER) in Period 1. Only 40 patients were randomized to Period 2, the randomized period, before the study was terminated; 190 patients entered Period 3. Data are only reported for the randomized period.

Period 1
Participant flow — Period 1
MilestonePeriod 1 Placebo and PAR/SERPeriod 2 Placebo and PAR/SER (Randomized Period)Period 2 Brexpiprazole and PAR/SER (Randomized Period)Period 3 Placebo and PAR/SER
Started417000
Completed231000
Not completed186000
Withdrew: Adverse event24000
Withdrew: Lack of efficacy4000
Withdrew: Non-compliance with imp6000
Withdrew: Protocol violation12000
Withdrew: Withdrawal by subject21000
Withdrew: Lost to follow-up40000
Withdrew: Administrative or other reason75000
Withdrew: Withdrawal of consent before treatment4000
Period 2
Participant flow — Period 2
MilestonePeriod 1 Placebo and PAR/SERPeriod 2 Placebo and PAR/SER (Randomized Period)Period 2 Brexpiprazole and PAR/SER (Randomized Period)Period 3 Placebo and PAR/SER
Started017230
Completed012140
Not completed0590
Withdrew: Adverse event0010
Withdrew: Withdrawal by subject0010
Withdrew: Administrative or other reason0570
Period 3
Participant flow — Period 3
MilestonePeriod 1 Placebo and PAR/SERPeriod 2 Placebo and PAR/SER (Randomized Period)Period 2 Brexpiprazole and PAR/SER (Randomized Period)Period 3 Placebo and PAR/SER
Started000190
Completed000119
Not completed00071
Withdrew: Adverse event0007
Withdrew: Non-compliance with imp0001
Withdrew: Protocol violation0006
Withdrew: Withdrawal by subject0009
Withdrew: Lost to follow-up0005
Withdrew: Administrative or other reason00043

Outcome measures

PrimaryPTSD Symptoms Using CAPS-2 Total Score

Clinician-Administered PTSD Scale Part 2 (CAPS-2): 17 items in criteria B, C and D (Corresponding to CAPS-2) will be administered to provide a total score. They are rated on a 5 point scale for frequency from 0 (never or none) to 4 (daily or almost every day), and intensity from 0 (none) to 4 (extreme). The sum of the 17 items gives a toal score ranging from 0 to 136, with a higher score indicating greater symptom severity.

Time frame:
Period 2: Baseline to Week 12 (of randomized period)
Reported as:
Mean · Score
PTSD Symptoms Using CAPS-2 Total Score
ScorePeriod 2 Absolute Mean at Baseline; Placebo and PAR/SERPeriod 2 Absolute Mean at Baseline; Brexpiprazole and PAR/SERPeriod 2 Absolute Mean at Week 12; Placebo and PAR/SERPeriod 2 Absolute Mean at Week 12; Brexpiprazole and PAR/SER
PTSD Symptoms Using CAPS-2 Total Score82.82 ± 12.9483.43 ± 13.1269.67 ± 20.2669.18 ± 18.17
SecondaryGlobal Clinical Impression Severity of Illness (CGI-S) Score

Clinical Global Impression - Severity of Illness (CGI-S) The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Period 2: Baseline to Week 12 (of randomized period)
Reported as:
Mean · Score
Global Clinical Impression Severity of Illness (CGI-S) Score
ScorePeriod 2 Absolute Mean at Baseline; Placebo and PAR/SERPeriod 2 Absolute Mean at Baseline; Brexpiprazole and PAR/SERPeriod 2 Absolute Mean at Week 12; Placebo and PAR/SERPeriod 2 Absolute Mean at Week 12; Brexpiprazole and PAR/SER
Global Clinical Impression Severity of Illness (CGI-S) Score4.24 ± 0.834.54 ± 0.733.73 ± 1.103.94 ± 0.83

Adverse events

Collected over Period 2: Baseline to Week 16 (randomized period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole + PAR/SER (Randomized Period)—0/23 (0%)3/23 (13%)
Placebo + PAR/SER (Randomized Period)—0/17 (0%)8/17 (47.1%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventBrexpiprazole + PAR/SER (Randomized Period)Placebo + PAR/SER (Randomized Period)
Accidental overdoseInjury, poisoning and procedural complications2/231/17
ConjunctivitisEye disorders0/231/17
GastroenteritisInfections and infestations0/231/17
PharyngitisInfections and infestations0/231/17
Upper respiratory tract infectionInfections and infestations0/231/17
Tendon ruptureInjury, poisoning and procedural complications0/231/17
HypercholesterolaemiaMetabolism and nutrition disorders0/231/17
Back painMusculoskeletal and connective tissue disorders1/231/17
Disturbance in attentionNervous system disorders0/231/17
GalactorrhoeaReproductive system and breast disorders0/231/17

Baseline characteristics

The all-patients-treated set (APTS) comprises all randomized patients who took at least one dose of brexpiprazole or placebo.

Age, Continuous
Age, Continuous(years)Period 2 Placebo and PAR/SER (Randomized Period)Period 2 Brexpiprazole and PAR/SER (Randomized Period)Total
Mean42.9 ± 11.847.6 ± 10.445.6 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Period 2 Placebo and PAR/SER (Randomized Period)Period 2 Brexpiprazole and PAR/SER (Randomized Period)Total
Female101121
Male71219
08

Study locations

59 sites
  • US004
    Los Angeles, California 90024, United States
  • US025
    Los Angeles, California 90102, United States
  • US024
    Riverside, California 92504, United States
  • US015
    San Diego, California 90103, United States
  • US008
    San Diego, California 92123, United States
  • US002
    Bradenton, Florida 34201, United States
  • US006
    Gainesville, Florida 32607, United States
  • US016
    Jacksonville, Florida 32256, United States
  • US020
    North Miami, Florida 33161, United States
  • US017
    Tampa, Florida 33609, United States
  • US012
    Indianapolis, Indiana 46260, United States
  • US021
    Roslindale, Massachusetts 02131, United States
  • US019
    Las Vegas, Nevada 89102, United States
  • US007
    Nashua, New Hampshire 03060, United States
  • US001
    Bronx, New York 10467, United States
  • US009
    Cincinnati, Ohio 45219, United States
  • US005
    Dayton, Ohio 45417, United States
  • US010
    Portland, Oregon 97210, United States
  • US014
    Norristown, Pennsylvania 19403, United States
  • US011
    Memphis, Tennessee 38119, United States
  • US003
    Austin, Texas 78731, United States
  • US026
    Seattle, Washington 98104, United States
  • EE001
    Tallinn, Estonia
  • FI002
    Helsinki, Finland
  • FI003
    Helsinki, Finland
  • FI001
    Kuopio, Finland
  • FI006
    Oulu, Finland
  • FI005
    Tampere, Finland
  • FI004
    Turku, Finland
  • FR002
    Fort de France, France
  • FR003
    Laxou, France
  • FR004
    Nimes Cedex 9, France
  • FR005
    Thuir Cedex, France
  • FR001
    Tours Cedex 9, France
  • IT005
    Andria, Italy
  • IT004
    Catania, Italy
  • IT003
    Lecce, Italy
  • IT001
    Pisa, Italy
  • IT002
    Siena, Italy
  • PL003
    Bialystok, Poland
  • PL004
    Gdansk, Poland
  • PL005
    Gdansk, Poland
  • PL001
    Leszno, Poland
  • PL002
    Lublin, Poland
  • RS006
    Belgrade, Serbia
  • RS004
    Nis, Serbia
  • RS005
    Novi Knezevac, Serbia
  • ZA006
    Bloemfontein, South Africa
  • ZA002
    Cape Town, South Africa
  • ZA003
    Cape Town, South Africa
  • ZA004
    Cape Town, South Africa
  • ZA005
    Cape Town, South Africa
  • ZA008
    Durban, South Africa
  • ZA007
    Port Elizabeth, South Africa
  • ZA001
    Pretoria, South Africa
  • ZA009
    Pretoria, South Africa
  • SE001
    Falun, Sweden
  • SE002
    Stockholm, Sweden
  • SE003
    Uppsala, Sweden
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2013
First posted
Nov 20, 2013
Start
Dec 2013
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results first posted
Mar 13, 2017
Last update
Mar 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01987960
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Nov 20, 2013
Start date
Dec 2013
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
Mar 13, 2017
Last update
Mar 13, 2017

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion